Drug intelligence / Profile preview

N-{4-[(Carboxymethyl)carbamoyl]benzoyl}-L-valyl-N-[(3S)-1,1,1-trifluoro-4-methyl-2-oxo-3-pentanyl]-L-prolinamide

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is a synthetic small molecule dipeptide derivative with the formula C26H33F3N4O7. It is known as an experimental inhibitor of chymotrypsin-like elastase family member CELA1 (chymotrypsin-like elastase family member I), a serine protease involved in the degradation of elastin and other proteins. The compound has not been approved for any clinical use and has no reported indications or completed clinical trials. Its primary mechanism of action is inhibition of CELA1 activity[6][7]. No additional pharmacological or therapeutic information is available.

Other names
2-((4-(((2S)-3-methyl-1-oxo-1-((2S)-2-( ((3S)-1,1,1-trifluoro - 4 - methyl - 2 - oxopentan - 3 - yl ) carbamoyl ) pyrrolidin - 1 - yl ) butan - 2 - yl ) carbamoyl ) phenyl ) formamido)acetic acidN-(4-( (Carboxymethyl)carbamoyl)benzoyl)-L-valyl-N-( (3S)- 1 , 1 , 1-trifluoro – 4 – methyl – 2 – oxo – 3 – pentanyl )– L–prolinamideMetabolomics Workbench ID148196
02

Targets

CELA1 (Chymotrypsin-like elastase family member 1)

Beyond the preview

Go deeper on N-{4-[(Carboxymethyl)carbamoyl]benzoyl}-L-valyl-N-[(3S)-1,1,1-trifluoro-4-methyl-2-oxo-3-pentanyl]-L-prolinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-{4-[(Carboxymethyl)carbamoyl]benzoyl}-L-valyl-N-[(3S)-1,1,1-trifluoro-4-methyl-2-oxo-3-pentanyl]-L-prolinamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call